Daily Stock Analysis, ACHV, Achieve Life Sciences Inc, priceseries

Achieve Life Sciences Inc. Daily Stock Analysis
Stock Information
Open
4.11
Close
4.16
High
4.50
Low
4.05
Previous Close
4.05
Daily Price Gain
0.11
YTD High
4.54
YTD High Date
Feb 22, 2019
YTD Low
1.16
YTD Low Date
Jan 14, 2019
YTD Price Change
2.88
YTD Gain
225.00%
52 Week High
14.31
52 Week High Date
May 24, 2018
52 Week Low
0.95
52 Week Low Date
May 23, 2018
52 Week Price Change
2.86
52 Week Gain
220.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
5.61
Jan 17. 2017
6.52
9 Trading Days
16.19%
Link
LONG
Aug 29. 2017
3.69
Aug 30. 2017
3.95
1 Trading Days
6.91%
Link
LONG
Oct 26. 2017
2.18
Oct 27. 2017
2.32
1 Trading Days
6.19%
Link
LONG
Dec 7. 2017
1.46
Dec 8. 2017
1.55
1 Trading Days
6.16%
Link
LONG
Dec 22. 2017
1.27
Dec 29. 2017
1.34
4 Trading Days
5.71%
Link
LONG
Jan 29. 2019
1.42
Feb 20. 2019
1.60
15 Trading Days
12.96%
Link
LONG
Feb 21. 2019
1.79
Mar 8. 2019
2.42
11 Trading Days
35.14%
Link
LONG
Mar 14. 2019
2.45
Mar 22. 2019
2.86
6 Trading Days
16.76%
Link
Company Information
Stock Symbol
ACHV
Exchange
NasdaqCM
Company URL
http://www.oncogenex.com
Company Phone
425-686-1500
CEO
Scott Daniel Cormack
Headquarters
Washington
Business Address
19820 NORTH CREEK PARKWAY, SUITE 201, BOTHELL, WA 98011
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000949858
About

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

Description

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.